Phase 2 N=30 The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse
Smoking
Primary: Latency to Initiate Ad-lib Smoking Session — 28.134; 45.861; 21.737 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
Breast Cancer
Primary: Pathologic Complete Response — 26 percentage of participants
Phase 2 N=78 Efficacy and Safety of Prepopik® in Children for Overall Colon Cleansing in Preparation for Colonoscopy
Need for Bowel Preparation
Primary: Percentage of Participants Defined by "Excellent" or "Good" in the Aronchick Scale — 50; 87.5; 81.3; 81.3 percentage of participants
Phase 2 N=5 PK/PD Comparison of Guanfacine ER and IR
Smoking
Primary: Plasma Trough Levels of Guanfacine — 3.40; 3.46; 5.92 ng/ml
Phase 2 N=522 Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse
Malaria, Vivax
Primary: Number of Participants With Recurrence-free Efficacy at 6 Months Post Dose — 35; 155; 83 Participants — p=<0.001
Phase 2 N=15 Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation
Leukemia
Primary: Overall Response (OR) — 3 Participants
Phase 2 N=16 CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)
Melanoma
Primary: Safety — 16 participants
Phase 2 N=42 A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
Lymphocytic Leukemia, Chronic
Primary: Overall Response Rate — 67.5 percentage of participants
Phase 2 N=169 Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
Primary Open-Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Intra-Ocular Pressure (IOP) at Week 2 — 24.99; 25.34; 23.65; 23.75 mm Hg
Phase 2 N=18 Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Epistaxis · Hereditary Hemorrhagic Telangiectasia
Primary: Severityof Epistaxis — -0.4578; -1.4375 units on a scale
Phase 2 N=27 Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Prostate Cancer
Primary: PSA Response — 14 Participants
Phase 2 N=30 Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
Breast Cancer · Metastatic Cancer
Primary: Number of Patients With Objective Treatment Response (Complete or Partial) in the CNS — 2 Participants
Phase 2 N=231 A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Follicular Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) as Determined by Modified Response and Progression…
Phase 2 N=103 A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Percentage of Participants With Complete Response and Partial Response (Objective Response Rate) — 7.5; 0; 3.1 percentage of participants
Phase 2 N=50 DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: The Percentage of Subjects With HPA Axis Suppression. — 36.4; 12.5 percentage of participants — p=0.086